WNT5A enhances resistance of melanoma cells to targeted BRAF inhibitors

Journal of Clinical Investigation

Volumn 124, Issue 7, 2014, Pages 2877-2890

  Anastas, Jamie N ^a,b   Kulikauskas, Rima M ^b   Tamir, Tigist ^b   Rizos, Helen ^c   Long, Georgina V ^c   Von Euw, Erika M ^d   Yang, Pei Tzu ^b   Chen, Hsiao Wang ^d   Haydu, Lauren ^c   Toroni, Rachel A ^b   Lucero, Olivia M ^b   Chien, Andy J ^b   Moon, Randall T ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; FRIZZLED PROTEIN; FRIZZLED PROTEIN 7; N [3 (5 CHLORO 1H PYRROLO[2,3 B]PYRIDINE 3 CARBONYL) 2,4 DIFLUOROPHENYL]PROPANESULFONAMIDE; PROTEIN KINASE B; UNCLASSIFIED DRUG; VEMURAFENIB; WNT5A PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER RESISTANCE; CARCINOGENESIS; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SENSITIZATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

BETA CATENIN; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FRIZZLED RECEPTORS; HUMANS; INDOLES; MELANOMA; MUTATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR PROTEIN-TYROSINE KINASES; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SULFONAMIDES; UP-REGULATION; WNT PROTEINS; WNT SIGNALING PATHWAY;

EID: 84903754178     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI70156     Document Type: Article

References (70)

1. Davies H, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417(6892):949-954. (Pubitemid 34716871)
2. Curtin JA, et al. Distinct sets of genetic alterations in melanoma. N Engl J Med. 2005;353(20):2135-2147. (Pubitemid 41653105)
3. Tsai J, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci U S A. 2008;105(8):3041-3046. (Pubitemid 351723664)
4. Joseph EW, et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc Natl Acad Sci U S A. 2010;107(33):14903-14908.
5. Flaherty KT, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010;363(9):809-819.
6. Sosman JA, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707-714.
7. Bollag G, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010;467(7315):596-599.
8. Chapman PB, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
9. Nazarian R, et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010;468(7326):973-977.
10. Wagle N, et al. Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol. 2011;29(22):3085-3096
11. Poulikakos PI, et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011;480(7377):387-390.
12. Flaherty KT, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694-1703.
13. Kim KB, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013;31(4):482-489.
14. Villanueva J, et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell. 2010;18(6):683-695.
15. Yadav V, et al. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. J Biol Chem. 2012;287(33):28087-28098.
16. Paraiso KHT, et al. PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression. Cancer Res. 2011;71(7):2750-2760.
17. Shao Y, Aplin AE. BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma. Cell Death Differ. 2012; 19(12):2029-2039.
18. Gembarska A, et al. MDM4 is a key therapeutic target in cutaneous melanoma. Nat Med. 2012; 18(8):1239-1247.
19. Moon RT, et al. Xwnt-5A: a maternal Wnt that affects morphogenetic movements after overexpression in embryos of Xenopus laevis. Dev Camb Engl. 1993;119(1):97-111. (Pubitemid 23279130)
20. Weeraratna AT. A Wnt-er wonderland-the complexity of Wnt signaling in melanoma. Cancer Metastasis Rev. 2005;24(2):237-250. (Pubitemid 40922797)
21. Bordonaro M, Tewari S, Cicco CE, Atamna W, Lazarova DL. A switch from canonical to noncanonical Wnt signaling mediates drug resistance in colon cancer cells. PLoS One. 2011;6(11):e27308.
22. Kobune M, et al. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism. Mol Cancer Ther. 2007;6(6):1774-1784. (Pubitemid 46954054)
23. Zhang H, et al. Interference of Frizzled 1 (FZD1) reverses multidrug resistance in breast cancer cells through the Wnt/β-catenin pathway. Cancer Lett. 2012;323(1):106-113.
24. Biechele TL, et al. Wnt/β-catenin signaling and AXIN1 regulate apoptosis triggered by inhibition of the mutant kinase BRAFV600E in human melanoma. Sci Signal. 2012;5(206):ra3.
25. Flaherty KT, Hodi FS, Fisher DE. From genes to drugs: targeted strategies for melanoma. Nat Rev Cancer. 2012;12(5):349-361.
26. Davies MA. The role of the PI3K-AKT pathway in melanoma. Cancer J Sudbury Mass. 2012;18(2):142-147.
27. Tap WD, et al. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia N Y N. 2010;12(8):637-649.
28. O'Connell MP, et al. Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discov. 2013;3(12):1378-1393.
29. Smalley KSM, Lioni M, Herlyn M. Life isn't flat: taking cancer biology to the next dimension. In Vitro Cell Dev Biol Anim. 2006;42(8-9):242-247. (Pubitemid 44851881)
30. Chien AJ, et al. Activated Wnt/beta-catenin signaling in melanoma is associated with decreased proliferation in patient tumors and a murine melanoma model. Proc Natl Acad Sci U S A. 2009; 106(4):1193-1198.
31. Yang P-T, et al. WLS inhibits melanoma cell proliferation through the β-catenin signalling pathway and induces spontaneous metastasis. EMBO Mol Med. 2012;4(12):1294-1307.
32. Li J, et al. WNT5A antagonizes WNT/beta-catenin signaling and is frequently silenced by promoter CpG methylation in esophageal squamous cell carcinoma. Cancer Biol Ther. 2010;10(6):617-624.
33. Roarty K, Baxley SE, Crowley MR, Frost AR, Serra R. Loss of TGF-βor Wnt5a results in an increase in Wnt/ β-catenin activity and redirects mammary tumour phenotype. Breast Cancer Res BCR. 2009;11(2):R19.
34. Biechele TL, Adams AM, Moon RT. Transcriptionbased reporters of Wnt/β-catenin signaling. Cold Spring Harb Protoc. 2009;2009(6):pdb. prot5223.
35. Ying J, et al. WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/β-catenin signaling, and is frequently methylated in colorectal cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(1):55-61. (Pubitemid 351377978)
36. Huang S-MA, et al. Tankyrase inhibition stabilizes axin and antagonizes Wnt signalling. Nature. 2009;461(7264):614-620.
37. Dissanayake SK, et al. The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition. J Biol Chem. 2007;282(23):17259-17271. (Pubitemid 47093253)
38. Weeraratna AT, et al. Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell. 2002;1(3):279-288. (Pubitemid 41039152)
39. O'Connell MP, et al. The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene. 2010;29(1):34-44.
40. Vlahos CJ, Matter WF, Hui KY, Brown RF. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J Biol Chem. 1994;269(7):5241-5248.
41. Gopal YNV, et al. Basal and treatment-induced activation of AKT mediates resistance to cell death by AZD6244 (ARRY-142886) in Braf-mutant human cutaneous melanoma cells. Cancer Res. 2010;70(21):8736-8747.
42. Su F, et al. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation. Cancer Res. 2012;72(4):969-978.
43. Deng W, et al. Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition. Pigment Cell Melanoma Res. 2012;25(2):248-258.
44. Atefi M, et al. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011;6(12):e28973.
45. Baryawno N, et al. Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/β-catenin pathway cross-talk and suppress medulloblastoma growth. Cancer Res. 2010;70(1):266-276.
46. Sánchez-Hernández I, Baquero P, Calleros L, Chiloeches A. Dual inhibition of (V600E)BRAF and the PI3K/AKT/mTOR pathway cooperates to induce apoptosis in melanoma cells through a MEK-independent mechanism. Cancer Lett. 2012;314(2):244-255.
47. Shao Y, Aplin AE. Akt3-mediated resistance to apoptosis in B-RAF-targeted melanoma cells. Cancer Res. 2010;70(16):6670-6681.
48. Angers S, Moon RT. Proximal events in Wnt signal transduction. Nat Rev Mol Cell Biol. 2009; 10(7):468-477.
49. Kikuchi A, Yamamoto H, Sato A, Matsumoto S. Wnt5a: its signalling, functions and implication in diseases. Acta Physiol Oxf Engl. 2012;204(1):17-33.
50. Bittner M, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature. 2000;406(6795):536-540. (Pubitemid 30625740)
51. Da Forno PD, et al. WNT5A expression increases during melanoma progression and correlates with outcome. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14(18):5825-5832.
52. Tímár J, Gyorffy B, Rásó E. Gene signature of the metastatic potential of cutaneous melanoma: too much for too little? Clin Exp Metastasis. 2010;27(6):371-387.
53. Gentile A, Lazzari L, Benvenuti S, Trusolino L, Comoglio PM. Ror1 is a pseudokinase that is crucial for Met-driven tumorigenesis. Cancer Res. 2011;71(8):3132-3141.
54. Zhang S, et al. ROR1 is expressed in human breast cancer and associated with enhanced tumor-cell growth. PLoS One. 2012;7(3):e31127.
55. Berndt JD, et al. Mindbomb 1, an E3 ubiquitin ligase, forms a complex with RYK to activate Wnt/β-catenin signaling. J Cell Biol. 2011;194(5):737-750.
56. Hoek KS, et al. Metastatic potential of melanomas defined by specific gene expression profiles with no BRAF signature. Pigment Cell Res. 2006;19(4):290-302. (Pubitemid 44015592)
57. Lin WM, et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res. 2008;68(3):664-673. (Pubitemid 351206741)
58. Griesmann H. WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer. Neoplasia. 2013;15(1):11-22.
59. Gowrishankar K, et al. Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J Invest Dermatol. 2012;132(7):1850-1859.
60. Jiang CC, et al. MEK-independent survival of B-RAFV600E melanoma cells selected for resistance to apoptosis induced by the RAF inhibitor PLX4720. Clin Cancer Res. 2011;17(4):721-730.
61. Straussman R, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487(7408):500-504.
62. Wilson TR, et al. Widespread potential for growthfactor-driven resistance to anticancer kinase inhibitors. Nature. 2012;487(7408):505-509.
63. Witze ES, Litman ES, Argast GM, Moon RT, Ahn NG. Wnt5a control of cell polarity and directional movement by polarized redistribution of adhesion receptors. Science. 2008;320(5874):365-369. (Pubitemid 351555657)
64. Von Maltzahn J, Bentzinger CF, Rudnicki MA. Wnt7a-Fzd7 signalling directly activates the Akt/ mTOR anabolic growth pathway in skeletal muscle. Nat Cell Biol. 2011;14(2):186-191.
65. King TD, Zhang W, Suto MJ, Li Y. Frizzled7 as an emerging target for cancer therapy. Cell Signal. 2012;24(4):846-851.
66. Yang L, et al. FZD7 has a critical role in cell proliferation in triple negative breast cancer. Oncogene. 2011;30(43):4437-4446.
67. Ueno K, et al. Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells. Br J Cancer. 2009;101(8):1374-1381.
68. Ueno K, et al. Frizzled-7 as a potential therapeutic target in colorectal cancer. Neoplasia. 2008;10(7):697-705. (Pubitemid 351883886)
69. Gurney A, et al. Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors. Proc Natl Acad Sci U S A. 2012;109(29):11717-11722.
70. Anastas JN, et al. A protein complex of SCRIB, NOS1AP and VANGL1 regulates cell polarity and migration, and is associated with breast cancer progression. Oncogene. 2012;31(32):3696-3708.